Pegloticase Research Articles

FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment

BackgroundA subset of patients develops refractory gout (RG) characterized by ongoing disease manifestations and inability to control serum urate (SUA) with conventional therapy. Pegloticase (PL) reduces SUA and improves signs...

FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR)

BackgroundPL is approved for treating RG at 8 mg IV every 2 wks. Phase 1 testing suggested that 8 mg IV every 3 wks might also be effective. We have...

AB1058 Time to resolution of tophi with urate lowering agents: A literature analysis of randomized trials

BackgroundThe tophus is a pathognomonic feature of chronic gout and may cause disability and joint damage. Accordingly, OMERACT has endorsed tophus measurement as a key domain in clinical trials of...